[
1. Gangat N, Patnaik M, Tefferi A. Myelodysplastic syndromes: Contemporary review and how we treat. Am J Hematol. 2016; 91(1): 76-89.
]Search in Google Scholar
[
2. Cihak A. Biological effects of 5-azacytidine in eukaryotes. Oncology. 1974; 30(5): 405-22.
]Search in Google Scholar
[
3. Kaminskas E, Farrell A, Wang Y, et al. FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension. Oncologist. 2005;10(3):176-82.
]Search in Google Scholar
[
4. Estey E. Epigenetics in clinical practice: the examples of azacitidine and decitabine in myelodysplasia and acute myeloid leukemia. Leukemia. 2013; 27(9):1803-12.
]Search in Google Scholar
[
5. Micheva I, Dimitrova S, Efraim M, et al. Outcome after azacitidine treatment in patients with high-risk myelodysplastic syndrome and acute myeloid leukemia in the Clinic of Hematology at St. Marina University Hospital, Varna. Scripta Scientifica Medica. 2018; 50(1):31-35
]Search in Google Scholar
[
6. Varbanova V, Anastasova-Postadzhiyan A, Nedeva A, et al. Outcome After Azacitidine Treatment in Patients with High Risk Myeolodysplastic Syndrome, Chronic Myelomonocytic Leukemia Type 2 and Acute Myeloid Leukemia – A Single Center Experience (Preliminary Data). Acta Medica Bulgarica. 2020;47:38-43.
]Search in Google Scholar
[
7. Tendas A, Cupelli L, Siniscalchi A, et al. Azacitidine in chronic myelomonocytic leukemia: an effective and manageable approach. Mediterr J Hematol Infect Dis. 2014;6(1): e2014020.
]Search in Google Scholar
[
8. Della Porta MG, Tuechler H, Malcovati L, et al. Validation of WHO classification-based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System (IPSS-R). A study of the International Working Group for Prognosis in Myelodysplasia (IWG-PM). Leukemia. 2015;29(7):1502-13.
]Search in Google Scholar
[
9. Raj K, John A, Ho A, et al. CDKN2B methylation status and isolated chromosome 7 abnormalities predict responses to treatment with 5-azacytidine. Leukemia. 2007; 21(9): 1937-44.
]Search in Google Scholar
[
10. Gore S, Baylin S, Sugar E, et al. Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res. 2006;66(12): 6361-9.
]Search in Google Scholar
[
11. Schanz J, Tuchler H, Sole F, et al. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol. 2012;30(8):820-9.
]Search in Google Scholar
[
12. Gangat N, Patnaik M, Begna K, et al. Primary Myelodysplastic Syndromes: The Mayo Clinic Experience With 1000 Patients. Mayo Clin Proc. 2015;90(12):1623-38.
]Search in Google Scholar
[
13. Wiktor A, Rybicki B, Piao ZS, et al. Clinical significance of Y chromosome loss in hematologic disease. Genes Chromosomes Cancer. 2000;27(1):11-6.
]Search in Google Scholar
[
14. Mufti G, Gore S, Santini V, et al. Influence of Karyotype On Overall Survival in Patients with Higher-Risk Myelodysplastic Syndrome Treated with Azacitidine or a Conventional Care Regimen. Blood. 2009;114(22):1755.
]Search in Google Scholar
[
15. Fenaux P, Mufti G. J, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10(3):223-32.
]Search in Google Scholar
[
16. Dohner H, Dolnik A, Tang L, et al. Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care. Leukemia. 2018;32(12):2546-2557.
]Search in Google Scholar
[
17. Usami E, Kimura M, Takenaka S et al. Continuity and efficacy of real-world use of azacitidine. Pharmazie. 2020;75(4):154-158.
]Search in Google Scholar
[
18. Muller-Thomas C, Schuster T, Peschel C, et al. A limited number of 5-azacitidine cycles can be effective treatment in MDS. Ann Hematol. 2009;88(3):213-9.
]Search in Google Scholar
[
19. Cseh A.M, Niemeyer C. M, Yoshimi A et al. Therapy with low-dose azacitidine for MDS in children and young adults: a retrospective analysis of the EWOG-MDS study group. Br J Haematol. 2016;172(6):930-6.
]Search in Google Scholar
[
20. Xie M, Jiang Q, Xie Y et al. Comparison between decitabine and azacitidine for the treatment of myelodysplastic syndrome: a meta-analysis with 1,392 participants. Clin Lymphoma Myeloma Leuk. 2015;15(1):22-8.
]Search in Google Scholar
